BeStock  
Stocks › Biotechnology › ODTX

Odyssey Therapeutics ODTX

US equityMarket cap rank #3341Biotechnology
$18.08 −$0.05 (-0.28%)
Market closed · Oct 8, 4:10 am ET · Last extended-hours $18.08 0.00%
Open$18.01
Prev close$18.13
Day range$17.83 – $18.84
Volume264.1K
Market cap$868.90M
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q2, ended Jun 2026

Revenue$0.00-100.0% YoY
Operating profit-$46.74M-10.0% YoY
Net profit-$52.79M-28.0% YoY
Diluted EPS-$1.74-16.3% YoY
Free cash flow-$34.69M-1.2% YoY
Operating cash flow-$34.51M

Revenue, last 6 quarters

$287.0KDec '23$1.8MDec '24$1.9MMar '25$959.0KJun '25$0.0Mar '26$0.0Jun '26

Net profit, last 6 quarters

$-28.9MDec '23$-35.9MDec '24$-38.4MMar '25$-41.2MJun '25$-38.3MMar '26$-52.8MJun '26

Diluted EPS by quarter

-1.23Dec '23-1.34Dec '24-1.39Mar '25-1.50Jun '25-0.81Mar '26-1.74Jun '26

Free cash flow by quarter

$-28.5MDec '23$-34.6MDec '24$-39.5MMar '25$-34.3MJun '25$-41.2MMar '26$-34.7MJun '26

Annual revenue

$0.0FY22$1.0MFY23$4.5MFY24$3.0MFY25

Profitability & balance sheet

Operating margin-161,887.9%
Net margin-161,643.4%
Return on equity-38.0%
Return on assets-33.1%
Return on invested capital-37.8%
Current ratio11.36
Liabilities / assets12.9%
Cash & investments$310.58M
Total debt$19.36M
Net cash (debt)$291.22M

Balance sheet

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2024 Q4 2024 ANNUAL
Convertible preferred securities $0.00 $703.56M $703.56M $514.89M $514.89M
Total Current Liabilities $28.30M $22.21M $26.48M $28.42M $28.42M
Payables $7.67M $8.22M $7.87M $6.32M $6.32M
-Accounts Payable $7.67M $8.22M $7.87M $6.32M $6.32M
Current Accrued Expenses $8.16M $4.42M $6.25M $3.83M $3.83M
Short-Term Debt and Capital Lease Obligation $5.47M $5.37M $5.21M $4.58M $4.58M
-Current Capital Lease Obligation $5.47M $5.37M $5.21M $4.58M $4.58M
Current Deferred Liabilities $3.17M $1.45M $64,000.00 $6.77M $6.77M
Other Current Liabilities $492,000.00 $399,000.00 $374,000.00 $753,000.00 $753,000.00
Total Non-Current Liabilities $34.33M $730.55M $731.59M $551.55M $551.55M
Long Term Debt and Capital Lease Obligation $19.36M $20.75M $21.90M $26.43M $26.43M
-Long Term Capital Lease Obligation $19.36M $20.75M $21.90M $26.43M $26.43M
Total Liabilities $62.63M $752.76M $758.07M $579.96M $579.96M
-Goodwill $14.10M $14.07M $14.33M $13.35M $13.35M
Goodwill and Other Intangible Assets $14.19M $14.23M $14.59M $13.92M $13.92M
Total Assets $483.85M $229.07M $269.79M $197.44M $197.44M
Total Current Assets $321.46M $185.10M $190.66M $135.51M $135.51M
Cash and Cash Equivalents & Short-Term Investments $310.58M $175.75M $181.36M $129.35M $129.35M
-Cash and Cash Equivalents $82.03M $35.72M $41.69M $59.14M $59.14M
-Short Term Investments $228.54M $140.03M $139.67M $70.22M $70.22M
Other Current Assets $10.89M $9.35M $9.30M $6.16M $6.16M
Total Non-Current Assets $162.39M $43.97M $79.13M $61.93M $61.93M
Net PPE $21.92M $24.48M $26.01M $39.47M $39.47M
-Gross PPE $34.95M $39.58M $40.17M $50.89M $50.89M
-Accumulated Depreciation -$13.04M -$15.11M -$14.16M -$11.42M -$11.42M
Investments and Advances $122.49M $0.00 $35.20M $0.00 $0.00
-Available for Sale Securities $122.49M – $35.20M – –
-Other Intangible Assets $86,000.00 $160,000.00 $262,000.00 $570,000.00 $570,000.00
Gains/Losses Not Affecting Retained Earnings -$505,000.00 -$147,000.00 $245,000.00 -$1.34M -$1.34M
Retained Earnings -$659.19M -$606.40M -$568.14M -$419.49M -$419.49M
Additional Paid-In Capital $1.08B $82.85M $79.62M $38.31M $38.31M
-Common Stock $5,000.00 $0.00 $0.00 $0.00 $0.00
Capital Stock $5,000.00 $0.00 $0.00 $0.00 $0.00
Stockholders' Equity $421.22M -$523.69M -$488.28M -$382.53M -$382.53M
Total Equity $421.22M -$523.69M -$488.28M -$382.53M -$382.53M
Other Non-Current Liabilities $14.97M $6.24M $6.13M $10.22M $10.22M
Other Non-Current Assets $3.79M $5.26M $3.33M $8.54M $8.54M

Cash flow

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q2 2025 Q1
Free Cash Flow -$34.69M -$41.18M -$130.70M -$34.29M -$39.55M
Effect of Exchange Rate Changes $104,000.00 $24,000.00 $316,000.00 $323,000.00 $69,000.00
Beginning Cash Balance $39.17M $44.90M $62.35M $58.12M $62.35M
Net Change in Cash $46.21M -$5.75M -$17.77M $107.77M -$4.29M
Depreciation & Depletion & Amortization $1.04M $1.17M $4.91M $1.27M $1.30M
Gain/Loss from Continuing Operations $639,000.00 -$33,000.00 $1.36M -$115,000.00 $495,000.00
Net cash flow from continuing operations -$34.51M -$41.04M -$129.47M -$34.26M -$38.62M
Operating Cash Flow -$34.51M -$41.04M -$129.47M -$34.26M -$38.62M
Other Non-Cash Items $9.68M $988,000.00 -$606,000.00 -$67,000.00 -$4.62M
Change in Working Capital $1.17M -$7.19M -$4.73M $2.42M -$5.28M
-Change in Prepaid Assets -$1.59M $3,000.00 -$3.21M -$863,000.00 $618,000.00
Ending Cash Balance $85.48M $39.17M $44.90M $166.21M $58.12M
Proceeds from Stock Option Exercised $586,000.00 $651,000.00 $3.19M $6,000.00 $235,000.00
Net Issuance Payments Of Debt -$46,000.00 -$24,000.00 – -$35,000.00 -$35,000.00
Net Cash Flow from Continuing Financing Activities $292.16M $484,000.00 $215.65M $118.72M $200,000.00
Financing Cash Flow $292.16M $484,000.00 $215.65M $118.72M $200,000.00
Net Investment Purchase and Sale -$211.54M $34.95M -$103.07M $23.25M $35.00M
Net PPE Purchase and Sale $95,000.00 -$148,000.00 -$875,000.00 $55,000.00 -$873,000.00
Net Cash Flow from Continuing Investing Activities -$211.44M $34.80M -$103.94M $23.31M $34.13M
Net cash flow from investing -$211.44M $34.80M -$103.94M $23.31M $34.13M
-Change in Other Current Liabilities -$1.26M -$1.23M -$4.60M -$843,000.00 -$1.07M
-Change in Other Current Assets $1.47M -$1.69M $5.16M $7.07M -$2.01M
-Change in Payables and Accrued Expense $2.55M -$4.28M -$2.09M -$2.94M -$2.83M
Net Income from Continuing Operations -$52.79M -$38.26M -$148.65M -$41.24M -$38.44M
Net Other Financing Charges – -$143,000.00 – – –
Net Preferred Stock Issuance – – $212.46M – –

Income statement

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q2 2025 Q1
Diluted EPS -$1.74 -$0.81 -$5.39 -$1.50 -$1.39
Basic EPS -$1.74 -$0.81 -$5.39 -$1.50 -$1.39
Net Income to Common Stockholders -$52.79M -$38.26M -$148.65M -$41.24M -$38.44M
Net Income to Parent Company -$52.79M -$38.26M -$148.65M -$41.24M -$38.44M
Profit from Continuing Operations -$52.79M -$38.26M -$148.65M -$41.24M -$38.44M
Net Profit -$52.79M -$38.26M -$148.65M -$41.24M -$38.44M
Tax -$8,000.00 $63,000.00 -$927,000.00 $30,000.00 $140,000.00
Pretax Profit -$52.80M -$38.20M -$149.57M -$41.21M -$38.30M
Other Non-Operating Income (Expenses) -$138,000.00 -$117,000.00 $1.20M -$154,000.00 -$289,000.00
-Less:Restructuring and Mergern & Acquisition $8.73M $109,000.00 -$4.05M -$566,000.00 -$5.65M
Special Income (Charges) -$8.73M -$109,000.00 $4.05M $566,000.00 $5.65M
Other Income (Expense) -$8.87M -$226,000.00 $5.25M $412,000.00 $5.36M
Non-Operating Interest Expense $20,000.00 $10,000.00 $17,000.00 $2,000.00 $2,000.00
Non-Operating Interest Income $2.83M $1.71M $6.35M $872,000.00 $1.16M
Total Revenue as Reported $0.00 $0.00 $2.98M $959,000.00 $1.92M
Total Operating Revenue $0.00 $0.00 $2.98M $959,000.00 $1.92M
Operating Expense $46.74M $39.67M $164.13M $43.45M $46.73M
Selling and Admin Expenses $10.51M $7.35M $37.52M $13.22M $7.95M
-General & Admin Expense $10.51M $7.35M $37.52M $13.22M $7.95M
Net Non-Operating Interest Income (Expense) $2.81M $1.70M $6.33M $870,000.00 $1.15M
Operating Profit -$46.74M -$39.67M -$161.16M -$42.49M -$44.81M
Research & Development $36.23M $32.32M $126.62M $30.23M $38.77M

Discussion

No comments yet — be the first to weigh in on ODTX.

Leave a comment

Scroll to Top